Please assess the completion status of the following clinical trial:

Trial Title: Tolvaptan for Patients With Acute Neurological Injuries

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with euvolemic or hypervolemic hyponatremia: serum Na \<135 meq/dl~* Inappropriately high urinary sodium excretion~Exclusion Criteria:~* Clinically evident hypovolemic hyponatremia~* Recent myocardial infarction or cardiac surgery~* Sustained ventricular tachycardia or fibrillation~* Systolic blood pressure of less than 90 mm Hg~* Serum creatinine concentration of more than 3 mg per deciliter~* History of, or biochemical evidence of, liver disease~* Serum sodium concentration less than 120 mmol per liter in association with neurologic impairment~* Urinary tract obstruction~* Use of other diuretics (furosemide, burinex, hydrochlorthiazide) that cannot be safely discontinued~* Concomitant use of hypertonic saline (prior use OK, if hypertonic is stopped within 1 hour of the first dose of Tolvaptan administration).~* History of chronic SIADH or known chronic hyponatremia from other causes (e.g. heart failure)~* Uncontrolled hypothyroidism or adrenal insufficiency~* Severe co-morbidities with life expectancy \<6 months~* CMO status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tolvaptan (Type: OTHER): Intervention arm. Open label, no control group

Based on this trial design, predict the completion outcome and termination type (if applicable).